XFOR | tickerfilter.com

Fundamental analysis

18%

Profitability 0%

Dept financing 21%

Liquidity 75%

Performance 20%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-1.12%

1 Month

-30.27%

3 Months

-62.78%

6 Months

-60.04%

1 Year

-83.29%

2 Year

-75.61%

Key data

Stock price

$0.21

P/E Ratio

0.00

DAY RANGE

$0.20 - $0.22

EPS

-$0.77

52 WEEK RANGE

$0.19 - $1.39

52 WEEK CHANGE

-$82.61

MARKET CAP

125.113 M

YIELD

N/A

SHARES OUTSTANDING

168.500 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-06-2025

BETA

2.11

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,974,820

AVERAGE 30 VOLUME

$1,815,230

Company detail

CEO: Paula S. Ragan
Region: US
Website: x4pharma.com
Employees: 80
IPO year: 2017

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor. The company is also developing X4P-002, a CXCR4 antagonist for the. treatment of brain cancers.

XFOR - X4 Pharmaceuticals, Inc